Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010015/S582

Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Medtronic, Inc. · Decision date Mar 6, 2026

FDA DECISIONP010015/S582

What did the FDA decide?

FDA records P010015/S582 as a supplement to PMA P010015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 6, 2026.

FDA approval order statement

to replace the Novec 72DA solvent with the PWR-4 3910 solvent during the component cleaning process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Mar 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010015/S582
Regulatory pathway
PMA supplement
Product code
LWP
Decision code
OK30
Decision date
Mar 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010015 · Original PMA

    MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM

  2. P010015/S567 · Related supplement

    Consulta CRT-P (C4TR01); Syncra CRT-P (C2TR01)

  3. P010015/S568 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CR T-

  4. P010015/S569 · Related supplement

    Consulta CRT-P C4TR01; Percepta Bipolar CRT-P W1TR01; Percepta Quadripolar CRT-P W4TR01; Serena Bipolar CRT-P W1TR02; Se

  5. P010015/S570 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C

  6. P010015/S571 · Related supplement

    Percepta Bipolar CRTP; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P;

  7. P010015/S572 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola

  8. P010015/S573 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Sola

  9. P010015/S575 · Related supplement

    Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol

  10. P010015/S574 · Related supplement

    Percepta Bipolar CRT-P W1TR01 NKE Percepta Quadripolar CRT-P W4TR01 NKE Serena Bipolar CRT-P W1TR02 NKE Serena Quadripol

  11. P010015/S576 · Related supplement

    Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRTP; Serena Quadripolar CRT-P; Solar

  12. P010015/S577 · Related supplement

    Percepta Bipolar CRT-P; Perceota Quadrioolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

  13. P010015/S582 received

    Application receipt date recorded by FDA.

  14. P010015/S578 · Related supplement

    Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T

  15. P010015/S579 · Related supplement

    Attain OTW LV Lead; Consulta CRT-P; Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Qua

  16. P010015/S580 · Related supplement

    Consulta CRT-P C4TR01 Syncra CRT-P C2TR01

  17. P010015/S582 · FDA decision

    30-Day Notice

  18. P010015/S584 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

  19. P010015/S586 · Related supplement

    Attain Bipolar OTW Lead; Attain OTW L V Lead

  20. P010015/S585 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRTP (W1TR02); Serena Quadripolar C

  21. P010015/S581 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  22. P010015/S583 · Related supplement

    Percepta Bipolar CRT-P (WlTR0l); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (WlTR02); Serena Quadripolar

  23. P010015/S587 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  24. P010015/S588 · Related supplement

    Consulta CRT-P (C4TR01); Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1T

  25. P010015/S589 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  26. P010015/S590 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  27. P010015/S591 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  28. P010015/S592 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010015

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalAug 28, 2001FDA
Medtronic, Inc.PMA supplementAug 6, 2025FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementSep 5, 2025FDA
Medtronic, Inc.PMA supplementOct 2, 2025FDA
Medtronic, Inc.PMA supplementOct 3, 2025FDA
Medtronic, Inc.PMA supplementOct 8, 2025FDA
Medtronic, Inc.PMA supplementDec 3, 2025FDA
Medtronic, Inc.PMA supplementDec 19, 2025FDA
Medtronic, Inc.PMA supplementJan 23, 2026FDA
Medtronic, Inc.PMA supplementJan 23, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementMar 27, 2026FDA
Medtronic, Inc.PMA supplementApr 15, 2026FDA
Medtronic, Inc.PMA supplementApr 23, 2026FDA
Medtronic, Inc.PMA supplementApr 30, 2026FDA
Medtronic, Inc.PMA supplementMay 14, 2026FDA
Medtronic, Inc.PMA supplementJul 16, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA
Medtronic, Inc.PMA supplementOct 5, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records